APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

NMDA Receptor Antagonist

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global NMDA Receptor Antagonist Market Outlook and Growth Opportunities 2026

Report ID 174017400430 December 2025193 pages

Choose your research edition.

Industry ResearchNMDA Receptor Antagonist Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal NMDA Receptor Antagonist Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal NMDA Receptor Antagonist Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal NMDA Receptor Antagonist Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal NMDA Receptor Antagonist Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global NMDA Receptor Antagonist market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for NMDA Receptor Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for NMDA Receptor Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for NMDA Receptor Antagonist is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the NMDA Receptor Antagonist market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the NMDA Receptor Antagonist market include Algernon Pharmaceuticals, ATAI Life Sciences, Avanir Pharmaceuticals, Axsome Therapeutics, Bexson Biomedical, Cessatech, DemeRx, PharmaTher and Relmada Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global NMDA Receptor Antagonist market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of NMDA Receptor Antagonist and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents NMDA Receptor Antagonist sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the NMDA Receptor Antagonist market size, projected growth trends, production technologies, key applications, and end-use industries.

NMDA Receptor Antagonist Segment by Company

Algernon Pharmaceuticals

ATAI Life Sciences

Avanir Pharmaceuticals

Axsome Therapeutics

Bexson Biomedical

Cessatech

DemeRx

PharmaTher

Relmada Therapeutics

Seelos Therapeutics

Small Pharma

UCB

NMDA Receptor Antagonist Segment by Type

Vaccine

Monoclonal Antibody

NMDA Receptor Antagonist Segment by Application

Parkinson's Disease

Alzheimer's Disease

Others

NMDA Receptor Antagonist Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global NMDA Receptor Antagonist status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions NMDA Receptor Antagonist market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify NMDA Receptor Antagonist significant trends, drivers, influence factors in global and regions.

6. To analyze NMDA Receptor Antagonist competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global NMDA Receptor Antagonist market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of NMDA Receptor Antagonist and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of NMDA Receptor Antagonist.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the NMDA Receptor Antagonist market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global NMDA Receptor Antagonist industry.

Chapter 3: Detailed analysis of NMDA Receptor Antagonist manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of NMDA Receptor Antagonist in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of NMDA Receptor Antagonist in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. NMDA Receptor Antagonist Industry Trends Table 2. NMDA Receptor Antagonist Industry Drivers Table 3. NMDA Receptor Antagonist Industry Opportunities and Challenges Table 4. NMDA Receptor Antagonist Industry Restraints Table 5. Global NMDA Receptor Antagonist Revenue by Company (US$ Million) & (2021-2026) Table 6. Global NMDA Receptor Antagonist Revenue Share by Company (2021-2026) Table 7. Global NMDA Receptor Antagonist Sales Volume by Company (K Units) & (2021-2026) Table 8. Global NMDA Receptor Antagonist Sales Volume Share by Company (2021-2026) Table 9. Global NMDA Receptor Antagonist Average Price (US$/Unit) of Company (2021-2026) Table 10. Global NMDA Receptor Antagonist Company Ranking, (2024-2026) & (USD Million) Table 11. Global NMDA Receptor Antagonist Key Company Manufacturing Base & Headquarters Table 12. Global NMDA Receptor Antagonist Company, Product Type & Application Table 13. Global NMDA Receptor Antagonist Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global NMDA Receptor Antagonist by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Vaccine Table 18. Significant Companies of Monoclonal Antibody Table 19. Global NMDA Receptor Antagonist Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global NMDA Receptor Antagonist Sales Volume by Type (2021-2026) & (K Units) Table 21. Global NMDA Receptor Antagonist Sales Volume by Type (2027-2032) & (K Units) Table 22. Global NMDA Receptor Antagonist Sales Volume Share by Type (2021-2026) Table 23. Global NMDA Receptor Antagonist Sales Volume Share by Type (2027-2032) Table 24. Global NMDA Receptor Antagonist Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global NMDA Receptor Antagonist Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global NMDA Receptor Antagonist Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global NMDA Receptor Antagonist Sales Value Share by Type (2021-2026) Table 28. Global NMDA Receptor Antagonist Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Parkinson's Disease Table 30. Significant Companies of Alzheimer's Disease Table 31. Significant Companies of Others Table 32. Global NMDA Receptor Antagonist Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global NMDA Receptor Antagonist Sales Volume by Application (2021-2026) & (K Units) Table 34. Global NMDA Receptor Antagonist Sales Volume by Application (2027-2032) & (K Units) Table 35. Global NMDA Receptor Antagonist Sales Volume Share by Application (2021-2026) Table 36. Global NMDA Receptor Antagonist Sales Volume Share by Application (2027-2032) Table 37. Global NMDA Receptor Antagonist Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global NMDA Receptor Antagonist Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global NMDA Receptor Antagonist Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global NMDA Receptor Antagonist Sales Value Share by Application (2021-2026) Table 41. Global NMDA Receptor Antagonist Sales Value Share by Application (2027-2032) Table 42. Global NMDA Receptor Antagonist Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global NMDA Receptor Antagonist Sales by Region (2021-2026) & (K Units) Table 44. Global NMDA Receptor Antagonist Sales Market Share by Region (2021-2026) Table 45. Global NMDA Receptor Antagonist Sales by Region (2027-2032) & (K Units) Table 46. Global NMDA Receptor Antagonist Sales Market Share by Region (2027-2032) Table 47. Global NMDA Receptor Antagonist Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global NMDA Receptor Antagonist Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global NMDA Receptor Antagonist Sales Value Share by Region (2021-2026) Table 50. Global NMDA Receptor Antagonist Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global NMDA Receptor Antagonist Sales Value Share by Region (2027-2032) Table 52. Global NMDA Receptor Antagonist Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global NMDA Receptor Antagonist Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global NMDA Receptor Antagonist Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global NMDA Receptor Antagonist Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global NMDA Receptor Antagonist Sales by Country (2021-2026) & (K Units) Table 57. Global NMDA Receptor Antagonist Sales Market Share by Country (2021-2026) Table 58. Global NMDA Receptor Antagonist Sales by Country (2027-2032) & (K Units) Table 59. Global NMDA Receptor Antagonist Sales Market Share by Country (2027-2032) Table 60. Global NMDA Receptor Antagonist Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global NMDA Receptor Antagonist Sales Value Market Share by Country (2021-2026) Table 62. Global NMDA Receptor Antagonist Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global NMDA Receptor Antagonist Sales Value Market Share by Country (2027-2032) Table 64. Algernon Pharmaceuticals Company Information Table 65. Algernon Pharmaceuticals Business Overview Table 66. Algernon Pharmaceuticals NMDA Receptor Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Algernon Pharmaceuticals NMDA Receptor Antagonist Product Portfolio Table 68. Algernon Pharmaceuticals Recent Development Table 69. ATAI Life Sciences Company Information Table 70. ATAI Life Sciences Business Overview Table 71. ATAI Life Sciences NMDA Receptor Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. ATAI Life Sciences NMDA Receptor Antagonist Product Portfolio Table 73. ATAI Life Sciences Recent Development Table 74. Avanir Pharmaceuticals Company Information Table 75. Avanir Pharmaceuticals Business Overview Table 76. Avanir Pharmaceuticals NMDA Receptor Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Avanir Pharmaceuticals NMDA Receptor Antagonist Product Portfolio Table 78. Avanir Pharmaceuticals Recent Development Table 79. Axsome Therapeutics Company Information Table 80. Axsome Therapeutics Business Overview Table 81. Axsome Therapeutics NMDA Receptor Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Axsome Therapeutics NMDA Receptor Antagonist Product Portfolio Table 83. Axsome Therapeutics Recent Development Table 84. Bexson Biomedical Company Information Table 85. Bexson Biomedical Business Overview Table 86. Bexson Biomedical NMDA Receptor Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Bexson Biomedical NMDA Receptor Antagonist Product Portfolio Table 88. Bexson Biomedical Recent Development Table 89. Cessatech Company Information Table 90. Cessatech Business Overview Table 91. Cessatech NMDA Receptor Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Cessatech NMDA Receptor Antagonist Product Portfolio Table 93. Cessatech Recent Development Table 94. DemeRx Company Information Table 95. DemeRx Business Overview Table 96. DemeRx NMDA Receptor Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. DemeRx NMDA Receptor Antagonist Product Portfolio Table 98. DemeRx Recent Development Table 99. PharmaTher Company Information Table 100. PharmaTher Business Overview Table 101. PharmaTher NMDA Receptor Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. PharmaTher NMDA Receptor Antagonist Product Portfolio Table 103. PharmaTher Recent Development Table 104. Relmada Therapeutics Company Information Table 105. Relmada Therapeutics Business Overview Table 106. Relmada Therapeutics NMDA Receptor Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. Relmada Therapeutics NMDA Receptor Antagonist Product Portfolio Table 108. Relmada Therapeutics Recent Development Table 109. Seelos Therapeutics Company Information Table 110. Seelos Therapeutics Business Overview Table 111. Seelos Therapeutics NMDA Receptor Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Seelos Therapeutics NMDA Receptor Antagonist Product Portfolio Table 113. Seelos Therapeutics Recent Development Table 114. Small Pharma Company Information Table 115. Small Pharma Business Overview Table 116. Small Pharma NMDA Receptor Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Small Pharma NMDA Receptor Antagonist Product Portfolio Table 118. Small Pharma Recent Development Table 119. UCB Company Information Table 120. UCB Business Overview Table 121. UCB NMDA Receptor Antagonist Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. UCB NMDA Receptor Antagonist Product Portfolio Table 123. UCB Recent Development Table 124. Key Raw Materials Table 125. Raw Materials Key Suppliers Table 126. NMDA Receptor Antagonist Distributors List Table 127. NMDA Receptor Antagonist Customers List Table 128. Research Programs/Design for This Report Table 129. Authors List of This Report Table 130. Secondary Sources Table 131. Primary Sources List of Figures Figure 1. NMDA Receptor Antagonist Product Image Figure 2. Global NMDA Receptor Antagonist Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global NMDA Receptor Antagonist Sales Value (2021-2032) & (US$ Million) Figure 4. Global NMDA Receptor Antagonist Sales (2021-2032) & (K Units) Figure 5. Global NMDA Receptor Antagonist Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global NMDA Receptor Antagonist Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Vaccine Image Figure 10. Monoclonal Antibody Image Figure 11. Global NMDA Receptor Antagonist Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global NMDA Receptor Antagonist Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global NMDA Receptor Antagonist Sales Volume Share by Type (2021-2032) Figure 14. Global NMDA Receptor Antagonist Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global NMDA Receptor Antagonist Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global NMDA Receptor Antagonist Sales Value Share by Type (2021-2032) Figure 17. Parkinson's Disease Image Figure 18. Alzheimer's Disease Image Figure 19. Others Image Figure 20. Global NMDA Receptor Antagonist Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global NMDA Receptor Antagonist Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global NMDA Receptor Antagonist Sales Volume Share by Application (2021-2032) Figure 23. Global NMDA Receptor Antagonist Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global NMDA Receptor Antagonist Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global NMDA Receptor Antagonist Sales Value Share by Application (2021-2032) Figure 26. Global NMDA Receptor Antagonist Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global NMDA Receptor Antagonist Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global NMDA Receptor Antagonist Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global NMDA Receptor Antagonist Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America NMDA Receptor Antagonist Sales Value (2021-2032) & (US$ Million) Figure 31. North America NMDA Receptor Antagonist Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe NMDA Receptor Antagonist Sales Value (2021-2032) & (US$ Million) Figure 33. Europe NMDA Receptor Antagonist Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific NMDA Receptor Antagonist Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific NMDA Receptor Antagonist Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America NMDA Receptor Antagonist Sales Value (2021-2032) & (US$ Million) Figure 37. South America NMDA Receptor Antagonist Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa NMDA Receptor Antagonist Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa NMDA Receptor Antagonist Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. NMDA Receptor Antagonist Value Chain Figure 125. Manufacturing Cost Structure Figure 126. NMDA Receptor Antagonist Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Vaccine
  • Monoclonal Antibody
Applications
  • Parkinson's Disease
  • Alzheimer's Disease
  • Others
Companies covered
  • Algernon Pharmaceuticals
  • ATAI Life Sciences
  • Avanir Pharmaceuticals
  • Axsome Therapeutics
  • Bexson Biomedical
  • Cessatech
  • DemeRx
  • PharmaTher
  • Relmada Therapeutics
  • Seelos Therapeutics
  • Small Pharma
  • UCB

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global NMDA Receptor Antagonist Sales Value (2021-2032)
  4. 1.2.2 Global NMDA Receptor Antagonist Sales Volume (2021-2032)
  5. 1.2.3 Global NMDA Receptor Antagonist Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 NMDA Receptor Antagonist Market Dynamics
  1. 2.1 NMDA Receptor Antagonist Industry Trends
  2. 2.2 NMDA Receptor Antagonist Industry Drivers
  3. 2.3 NMDA Receptor Antagonist Industry Opportunities and Challenges
  4. 2.4 NMDA Receptor Antagonist Industry Restraints
3 NMDA Receptor Antagonist Market by Company
  1. 3.1 Global NMDA Receptor Antagonist Company Revenue Ranking in 2025
  2. 3.2 Global NMDA Receptor Antagonist Revenue by Company (2021-2026)
  3. 3.3 Global NMDA Receptor Antagonist Sales Volume by Company (2021-2026)
  4. 3.4 Global NMDA Receptor Antagonist Average Price by Company (2021-2026)
  5. 3.5 Global NMDA Receptor Antagonist Company Ranking (2024-2026)
  6. 3.6 Global NMDA Receptor Antagonist Company Manufacturing Base and Headquarters
  7. 3.7 Global NMDA Receptor Antagonist Company Product Type and Application
  8. 3.8 Global NMDA Receptor Antagonist Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global NMDA Receptor Antagonist Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 NMDA Receptor Antagonist Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 NMDA Receptor Antagonist Market by Type
  1. 4.1 NMDA Receptor Antagonist Type Introduction
  2. 4.1.1 Vaccine
  3. 4.1.2 Monoclonal Antibody
  4. 4.2 Global NMDA Receptor Antagonist Sales Volume by Type
  5. 4.2.1 Global NMDA Receptor Antagonist Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global NMDA Receptor Antagonist Sales Volume by Type (2021-2032)
  7. 4.2.3 Global NMDA Receptor Antagonist Sales Volume Share by Type (2021-2032)
  8. 4.3 Global NMDA Receptor Antagonist Sales Value by Type
  9. 4.3.1 Global NMDA Receptor Antagonist Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global NMDA Receptor Antagonist Sales Value by Type (2021-2032)
  11. 4.3.3 Global NMDA Receptor Antagonist Sales Value Share by Type (2021-2032)
5 NMDA Receptor Antagonist Market by Application
  1. 5.1 NMDA Receptor Antagonist Application Introduction
  2. 5.1.1 Parkinson's Disease
  3. 5.1.2 Alzheimer's Disease
  4. 5.1.3 Others
  5. 5.2 Global NMDA Receptor Antagonist Sales Volume by Application
  6. 5.2.1 Global NMDA Receptor Antagonist Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global NMDA Receptor Antagonist Sales Volume by Application (2021-2032)
  8. 5.2.3 Global NMDA Receptor Antagonist Sales Volume Share by Application (2021-2032)
  9. 5.3 Global NMDA Receptor Antagonist Sales Value by Application
  10. 5.3.1 Global NMDA Receptor Antagonist Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global NMDA Receptor Antagonist Sales Value by Application (2021-2032)
  12. 5.3.3 Global NMDA Receptor Antagonist Sales Value Share by Application (2021-2032)
6 NMDA Receptor Antagonist Regional Sales and Value Analysis
  1. 6.1 Global NMDA Receptor Antagonist Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global NMDA Receptor Antagonist Sales by Region (2021-2032)
  3. 6.2.1 Global NMDA Receptor Antagonist Sales by Region: 2021-2026
  4. 6.2.2 Global NMDA Receptor Antagonist Sales by Region (2027-2032)
  5. 6.3 Global NMDA Receptor Antagonist Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global NMDA Receptor Antagonist Sales Value by Region (2021-2032)
  7. 6.4.1 Global NMDA Receptor Antagonist Sales Value by Region: 2021-2026
  8. 6.4.2 Global NMDA Receptor Antagonist Sales Value by Region (2027-2032)
  9. 6.5 Global NMDA Receptor Antagonist Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America NMDA Receptor Antagonist Sales Value (2021-2032)
  12. 6.6.2 North America NMDA Receptor Antagonist Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe NMDA Receptor Antagonist Sales Value (2021-2032)
  15. 6.7.2 Europe NMDA Receptor Antagonist Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific NMDA Receptor Antagonist Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific NMDA Receptor Antagonist Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America NMDA Receptor Antagonist Sales Value (2021-2032)
  21. 6.9.2 South America NMDA Receptor Antagonist Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa NMDA Receptor Antagonist Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa NMDA Receptor Antagonist Sales Value Share by Country, 2025 VS 2032
7 NMDA Receptor Antagonist Country-level Sales and Value Analysis
  1. 7.1 Global NMDA Receptor Antagonist Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global NMDA Receptor Antagonist Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global NMDA Receptor Antagonist Sales by Country (2021-2032)
  4. 7.3.1 Global NMDA Receptor Antagonist Sales by Country (2021-2026)
  5. 7.3.2 Global NMDA Receptor Antagonist Sales by Country (2027-2032)
  6. 7.4 Global NMDA Receptor Antagonist Sales Value by Country (2021-2032)
  7. 7.4.1 Global NMDA Receptor Antagonist Sales Value by Country (2021-2026)
  8. 7.4.2 Global NMDA Receptor Antagonist Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt NMDA Receptor Antagonist Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt NMDA Receptor Antagonist Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt NMDA Receptor Antagonist Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Algernon Pharmaceuticals
  2. 8.1.1 Algernon Pharmaceuticals Company Information
  3. 8.1.2 Algernon Pharmaceuticals Business Overview
  4. 8.1.3 Algernon Pharmaceuticals NMDA Receptor Antagonist Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Algernon Pharmaceuticals NMDA Receptor Antagonist Product Portfolio
  6. 8.1.5 Algernon Pharmaceuticals Recent Developments
  7. 8.2 ATAI Life Sciences
  8. 8.2.1 ATAI Life Sciences Company Information
  9. 8.2.2 ATAI Life Sciences Business Overview
  10. 8.2.3 ATAI Life Sciences NMDA Receptor Antagonist Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 ATAI Life Sciences NMDA Receptor Antagonist Product Portfolio
  12. 8.2.5 ATAI Life Sciences Recent Developments
  13. 8.3 Avanir Pharmaceuticals
  14. 8.3.1 Avanir Pharmaceuticals Company Information
  15. 8.3.2 Avanir Pharmaceuticals Business Overview
  16. 8.3.3 Avanir Pharmaceuticals NMDA Receptor Antagonist Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Avanir Pharmaceuticals NMDA Receptor Antagonist Product Portfolio
  18. 8.3.5 Avanir Pharmaceuticals Recent Developments
  19. 8.4 Axsome Therapeutics
  20. 8.4.1 Axsome Therapeutics Company Information
  21. 8.4.2 Axsome Therapeutics Business Overview
  22. 8.4.3 Axsome Therapeutics NMDA Receptor Antagonist Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Axsome Therapeutics NMDA Receptor Antagonist Product Portfolio
  24. 8.4.5 Axsome Therapeutics Recent Developments
  25. 8.5 Bexson Biomedical
  26. 8.5.1 Bexson Biomedical Company Information
  27. 8.5.2 Bexson Biomedical Business Overview
  28. 8.5.3 Bexson Biomedical NMDA Receptor Antagonist Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Bexson Biomedical NMDA Receptor Antagonist Product Portfolio
  30. 8.5.5 Bexson Biomedical Recent Developments
  31. 8.6 Cessatech
  32. 8.6.1 Cessatech Company Information
  33. 8.6.2 Cessatech Business Overview
  34. 8.6.3 Cessatech NMDA Receptor Antagonist Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Cessatech NMDA Receptor Antagonist Product Portfolio
  36. 8.6.5 Cessatech Recent Developments
  37. 8.7 DemeRx
  38. 8.7.1 DemeRx Company Information
  39. 8.7.2 DemeRx Business Overview
  40. 8.7.3 DemeRx NMDA Receptor Antagonist Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 DemeRx NMDA Receptor Antagonist Product Portfolio
  42. 8.7.5 DemeRx Recent Developments
  43. 8.8 PharmaTher
  44. 8.8.1 PharmaTher Company Information
  45. 8.8.2 PharmaTher Business Overview
  46. 8.8.3 PharmaTher NMDA Receptor Antagonist Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 PharmaTher NMDA Receptor Antagonist Product Portfolio
  48. 8.8.5 PharmaTher Recent Developments
  49. 8.9 Relmada Therapeutics
  50. 8.9.1 Relmada Therapeutics Company Information
  51. 8.9.2 Relmada Therapeutics Business Overview
  52. 8.9.3 Relmada Therapeutics NMDA Receptor Antagonist Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Relmada Therapeutics NMDA Receptor Antagonist Product Portfolio
  54. 8.9.5 Relmada Therapeutics Recent Developments
  55. 8.10 Seelos Therapeutics
  56. 8.10.1 Seelos Therapeutics Company Information
  57. 8.10.2 Seelos Therapeutics Business Overview
  58. 8.10.3 Seelos Therapeutics NMDA Receptor Antagonist Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Seelos Therapeutics NMDA Receptor Antagonist Product Portfolio
  60. 8.10.5 Seelos Therapeutics Recent Developments
  61. 8.11 Small Pharma
  62. 8.11.1 Small Pharma Company Information
  63. 8.11.2 Small Pharma Business Overview
  64. 8.11.3 Small Pharma NMDA Receptor Antagonist Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Small Pharma NMDA Receptor Antagonist Product Portfolio
  66. 8.11.5 Small Pharma Recent Developments
  67. 8.12 UCB
  68. 8.12.1 UCB Company Information
  69. 8.12.2 UCB Business Overview
  70. 8.12.3 UCB NMDA Receptor Antagonist Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 UCB NMDA Receptor Antagonist Product Portfolio
  72. 8.12.5 UCB Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 NMDA Receptor Antagonist Value Chain Analysis
  2. 9.1.1 NMDA Receptor Antagonist Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 NMDA Receptor Antagonist Sales Mode & Process
  6. 9.2 NMDA Receptor Antagonist Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 NMDA Receptor Antagonist Distributors
  9. 9.2.3 NMDA Receptor Antagonist Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst